Search Results

CO-1686 50mg 50mg  | Purity Not Available

Adooq Bioscience

CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC).

More Information Supplier Page

CO-1686 5mg 5mg  | Purity Not Available

Adooq Bioscience

CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC).

More Information Supplier Page

CO-1686 25mg 25mg  | Purity Not Available

Adooq Bioscience

CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC).

More Information Supplier Page

CO-1686 10mM * 1mL in DMSO 10mM * 1mL in DMSO  | Purity Not Available

Adooq Bioscience

CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC).

More Information Supplier Page

Laninamivir 1mg 1mg  | Purity Not Available

Adooq Bioscience

Laninamivir is a neuraminidase inhibitor which is being researched for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B.

More Information Supplier Page